My research has focused on the development and validation of novel molecular probes from preclinical research to translational PET imaging and therapy. These imaging agents are built upon a number of platforms including peptides, small molecules, antibodies, and nanostructures and are radiolabeled with various radionuclides according to the biological half-life of the biomolecules and decay half-life of the radionuclides. Through the collaboration with other investigators, I have translated four imaging agents for human imaging including 2 radiolabeled antibodies for cancer patients PET imaging, a targeted nanoparticle for human atherosclerosis and a CCR2 targeted ECLi1 peptide for human inflammation imaging.
- 2000: MS, environmental science, Zhejiang University, Hangzhou, Zhejiang, China
- 2007: PhD, radiochemistry, University of Missouri, Columbia
- 2007 - 2011: Postdoctoral fellow, Washington University, St. Louis